NewAmsterdam Pharma (NASDAQ:NAMS) Insider Buys $17,332.80 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) insider Juliette Berangere Audet acquired 1,104 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, September 26th. The shares were bought at an average price of $15.70 per share, with a total value of $17,332.80. Following the transaction, the insider now directly owns 1,104 shares in the company, valued at approximately $17,332.80. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $17.43 on Thursday. NewAmsterdam Pharma has a 1 year low of $5.63 and a 1 year high of $26.35. The company’s fifty day moving average is $16.47 and its two-hundred day moving average is $18.91.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.08. The company had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $2.20 million. On average, sell-side analysts anticipate that NewAmsterdam Pharma will post -2.06 earnings per share for the current year.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds have recently added to or reduced their stakes in the stock. Banque Cantonale Vaudoise acquired a new stake in NewAmsterdam Pharma during the 2nd quarter worth approximately $38,000. Sei Investments Co. lifted its position in NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after acquiring an additional 8,087 shares during the period. Wolverine Asset Management LLC lifted its position in NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after acquiring an additional 8,394 shares during the period. Rosalind Advisors Inc. acquired a new stake in NewAmsterdam Pharma during the 2nd quarter worth approximately $194,000. Finally, Yarbrough Capital LLC acquired a new stake in NewAmsterdam Pharma during the 1st quarter worth approximately $567,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NAMS has been the topic of several research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $31.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Piper Sandler reiterated an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Finally, Needham & Company LLC initiated coverage on NewAmsterdam Pharma in a report on Wednesday, August 28th. They issued a “buy” rating and a $36.00 target price for the company. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of “Buy” and an average price target of $33.80.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.